Form 4: Sonoma Pharmaceuticals Controller Awarded 10,000 Restricted Stock Units

Sonoma Pharmaceuticals, Inc. Controller John Dal Poggetto was granted 10,000 restricted stock units, vesting over three years or upon a change of control, for services performed.

Summary

• John Dal Poggetto, Controller of Sonoma Pharmaceuticals, Inc. (SNOA), was granted 10,000 Restricted Stock Units (RSUs).
• The RSUs were awarded on June 19, 2025, for services performed.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs vest on the third anniversary of the grant date (June 19, 2028) or upon a change of control.
• Following this transaction, Mr. Dal Poggetto beneficially owns 20,250 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a key officer is a positive step for aligning management incentives with long-term shareholder value and retaining talent, reflecting standard corporate governance practices.

Positives

• The grant of Restricted Stock Units aligns the Controller's interests with long-term shareholder value.
• The vesting schedule encourages retention of key management personnel.

Negatives

• The grant does not provide immediate cash compensation or direct share ownership to the recipient.

Risks

• The value of the RSUs is contingent on the future performance of Sonoma Pharmaceuticals' common stock.
• Vesting is subject to continued employment or a change of control, meaning the RSUs could be forfeited if conditions are not met.

Future Outlook

The 10,000 Restricted Stock Units granted to Controller John Dal Poggetto are set to vest on June 19, 2028, or upon a change of control, aligning future compensation with long-term company performance.

Industry Context

This is a standard executive compensation practice in many industries, including pharmaceuticals, to align management incentives with shareholder interests and promote long-term retention.

Comparison to Industry Standards

• Granting RSUs to key executives is a common practice across various industries, including pharmaceuticals, to incentivize long-term performance and retention.
• The specific number of units and vesting schedule would typically be benchmarked against peer companies of similar size and stage, though this document does not provide such comparative data.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential long-term benefit from aligned management incentives; potential future dilution upon RSU vesting (standard for equity compensation).
• Employees: Reflects ongoing executive compensation practices within the company.

Next Steps

• Continued employment of John Dal Poggetto to ensure vesting of RSUs.
• Potential future conversion of RSUs into common stock upon vesting.

Key Dates

Keywords

Sonoma Pharmaceuticals, SNOA, Restricted Stock Units, RSU, executive compensation, insider transaction, Form 4, Controller, equity grant